Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial
RCT (n=5204) found testosterone replacement did not significantly reduce the risk of prediabetes progressing to diabetes vs placebo (e.g. 0.7% vs 1.4% at 6 months, 10.1% vs 14.6% at 24 months, 12.8% vs 15.8% at 36 months, 13.4% vs 15.7% at 48 months) or improve glycaemic control.
Source:
JAMA Internal Medicine
SPS commentary:
Editorial suggests the only indication for testosterone replacement in men with hypogonadism remains treatment of bothersome symptoms of hypogonadism, and that this study suggests that testosterone replacement will not benefit glycaemic control in men without hypogonadism, despite the inappropriately high rates of use in this group.